Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Cancer Discov. 2018 Nov 8;9(3):370–383. doi: 10.1158/2159-8290.CD-18-0774

Table 3:

Overall response rate (CR, CRi, PR, HI) by baseline characteristics.

No Response (n=47) Response (n=23) p-value
N % (mean) N % (mean)

Age 0.79
  <60 9 19 5 22
  >/=60 38 81 18 78
Age 0.67
  <70 23 49 10 43
  >/=70 24 51 13 57
Salvage status 0.20
  S1 19 40 13 57
  >S1 28 60 10 43
Salvage status 0.12
  S1/S2 34 72 21 91
  >S2 13 28 2 9
Diagnosis 0.54
  AML - de novo 25 53 14 61
  Secondary AML 22 47 9 39
Prior ASCT 0.52
  Yes 10 21 3 13
  No 37 79 20 87
Prior HMA 0.01
  Yes 35 74 10 57
  No 12 26 13 43
Cytogenetic 0.13
  Diploid 13 28 12 52
  miscellaneous 16 34 5 22
  −5/−7/complex 18 38 6 26
TP53 0.23
  Negative 34 72 20 87
  Positive 13 28 3 13
IDH1 0.99
  Negative 43 91 21 91
  Positive 4 9 2 9
IDH2 0.46
  Negative 42 89 19 83
  Positive 5 11 4 17
RAS 0.14
  Negative 43 91 18 78
  Positive 4 9 5 22
ASXL1 0.03
  Negative 43 91 16 70
  Positive 4 9 7 30
BM BL>/=30
  No 19 40 12 52 0.35
  Yes 28 60 11 48
BM BL>/=20 0.02
  No 8 17 10 43
  Yes 39 83 13 57
BM BL>/=10 0.10
  No 3 6 5 22
  Yes 44 94 18 78
WBC>10 0.03
  No 34 72 22 96
  Yes 13 28 1 4
PLT>50 0.43
  No 33 70 14 61
  Yes 14 30 9 39
BM pretherapy CD3+ 23 (17.56) 19 (32.47) 0.042
PB pretherapy CD3+ 22 (21.83) 18 (45.07) 0.0058

Abbreviations: N: number, ORR: overall response rate, HMA: hypomethylating agent, SCT: Allogeneic stem cell transplant, BM: Bone marrow, PB: peripheral blood.